Prostate Cancer | Clinical

SPOTLIGHT Shines on Inadequacy of Standard Imaging in Prostate Cancer

June 24, 2022

Mark T. Fleming, MD, discusses the potential impact of positive data from the phase 3 SPOTLIGHT study, which assessed the how 18F-rhPSMA-7.3 PET scan use in male patients with biochemical recurrence of prostate cancer affects upstaging in comparison with conventional imaging.

Examining Molecular Subtyping in Prostate Cancer

June 24, 2022

In an interview with Targeted Oncology, Adam Weiner, MD, discussed molecular subtyping for prostate cancer based on basal and luminal cell-of-origin and how such research may impact the future of this space.

Sabizabulin for the Treatment of Men With mCRPC

June 17, 2022

Mark Markowski, MD, PhD, discusses the design of a phase 1B/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who have had treatment and progression on an androgen receptor–targeting agent.

CARD Trial Shows Survival and QOL Benefits of Cabazitaxel in mCRPC

June 15, 2022

During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of cabazitaxel for patients with metastatic castration-resistant prostate cancer. This is part 1 of 2 articles based on this event.